v3.25.3

Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 1,673,218	$ 3,502,077
Unbilled receivable	4,411	124,115
Prepaid expenses and other current assets	1,250,641	1,718,490
Total current assets	2,928,270	5,344,682
Property and equipment, net	123,643
Other assets	127,551	252,550
Total assets	3,179,464	5,597,232
Current liabilities:
Accounts payable	463,458	1,357,079
Accrued expenses and other liabilities	1,453,555	548,458
Notes payable and accrued interest	387,702	301,660
Total current liabilities	2,304,715	2,207,197
Long-term liabilities:
Other long-term liabilities	35	10,096
Total long-term liabilities	35	10,096
Total liabilities	2,304,750	2,217,293
Commitments and contingencies (Note 7)
Stockholders’ equity
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at September 30, 2025 and December 31, 2024
Common stock, $0.0001 par value, 250,000,000 shares authorized at September 30, 2025 and December 31, 2024; 3,181,080 and 1,355,779 shares issued at September 30, 2025 and December 31, 2024, respectively; 3,181,074 and 1,355,773 shares outstanding at September 30, 2025 and December 31, 2024, respectively	320	136
Additional paid-in capital	138,155,394	133,252,585
Accumulated deficit	(136,952,351)	(129,544,299)
Total Ensysce Biosciences, Inc. stockholders’ equity	1,203,363	3,708,422
Noncontrolling interests in stockholders’ equity	(328,649)	(328,483)
Total stockholders’ equity	874,714	3,379,939
Total liabilities and stockholders’ equity	$ 3,179,464	$ 5,597,232

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Ensysce Biosciences, Inc. 10-Q